Home » Healthcare » Neuropathic Pain Market

Neuropathic Pain Market By Type (Painful Diabetic Peripheral Neuropathy, Autonomic Neuropathy, Focal Neuropathy, Proximal Neuropathy); By Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy); By Diagnosis (Imaging, Blood Tests and Physical Examination); By Treatment (Medications, Multimodal Therapy); By End User (Hospitals, Clinics, Research Organization); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 34373 | Report Format : PDF
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Neuropathic Pain Market Size 2023  USD 8,379.70 million
Neuropathic Pain Market, CAGR  5.94%.
Neuropathic Pain Market Size 2032  USD 14,535.46 million

Market Overview:

The neuropathic pain market is poised for substantial growth, with projections indicating an increase from USD 8,379.70 million in 2023 to an estimated USD 14,535.46 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 5.94%. Key drivers fueling this growth include the escalating prevalence of neuropathic pain conditions globally. Chronic diseases such as diabetes, shingles, and post-herpetic neuralgia, coupled with an aging population, contribute to the rising incidence of neuropathic pain. Furthermore, there is a notable unmet medical need for effectively managing neuropathic pain, creating a demand for innovative and improved therapeutic interventions.

The market is witnessing a paradigm shift toward targeted therapies with fewer side effects. The growing awareness of neuropathic pain among healthcare professionals and the public has resulted in earlier diagnoses and treatment initiation, fostering market expansion. The pharmaceutical industry’s active development of novel medications, including those with unique mechanisms of action such as sodium channel blockers and N-methyl-D-aspartate (NMDA) receptor antagonists, adds to the momentum of the neuropathic pain market.

Emerging trends in neuropathic pain management include the adoption of combination therapies to enhance efficacy and manage side effects. Non-invasive pain management techniques like spinal cord stimulation and neurostimulation devices are gaining interest. Additionally, the integration of telemedicine and digital therapeutics for remote patient monitoring and personalized treatment plans is becoming more prevalent. The exploration of cannabis-based medications for chronic pain, including neuropathic pain, represents a noteworthy trend with potential opportunities for new product development.

While opportunities abound in this market, challenges include the high cost of certain treatments, limiting patient access, and straining healthcare budgets. Addressing the need for improved diagnostic tools for neuropathic pain and streamlining the regulatory landscape for new medications are critical aspects that could further accelerate advancements in the field and improve patient outcomes.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Market Drivers:

The neuropathic pain market is set for significant growth, projected to reach USD 14,535.46 million by 2032, with a compound annual growth rate (CAGR) of 5.94%. This expansion is attributed to a confluence of factors:

  1. Increased Prevalence of Underlying Conditions: A notable rise in conditions such as diabetes, as reported by the International Diabetes Federation, is a major contributing factor. The federation highlighted that 537 million adults globally were living with diabetes in 2021, with projections reaching 643 million by 2030 and 783 million by 2045. Additionally, the aging global population faces higher risks of diabetes, shingles, and neurological disorders, thereby fueling the demand for neuropathic pain management solutions. The growing incidence of cancer and the neuropathic pain resulting from cancer treatments, such as chemotherapy-induced nerve damage, also plays a critical role in escalating the need for effective therapies.
  2. Growing Awareness and Improved Diagnosis: Advances in diagnostic technologies have enabled earlier and more accurate detection of neuropathic pain, leading to prompt and more effective treatment. Increased public awareness, driven by campaigns and educational initiatives like the International Association for the Study of Pain’s Global Year Against Neuropathic Pain campaign, has empowered individuals to seek medical help. This, in turn, has resulted in a higher number of diagnosed cases and bolstered the demand for treatment options.
  3. Evolving Treatment Landscape and Unmet Needs: Despite the availability of certain medications and therapies, there remains a significant gap in the effective management of neuropathic pain. This has spurred ongoing research and development efforts aimed at discovering novel therapeutic strategies, thus opening market opportunities for innovative treatments. The industry is particularly focused on treatments that offer improved efficacy, fewer side effects, and the inclusion of non-invasive pain management techniques.
  4. Increasing Healthcare Expenditures and Government Initiatives: The rise in global healthcare spending has led to enhanced allocation of resources towards the management of chronic pain, including neuropathic pain. Recognizing the impact of chronic pain, governments across the world have been implementing initiatives to improve access to pain management therapies, thereby creating a supportive environment for the growth of the neuropathic pain market.

The interconnected dynamics of these drivers underscore the complex and growing nature of the neuropathic pain market, highlighting both the challenges and opportunities within this evolving landscape.

Market Trends:

  1. Rising Prevalence of Underlying Conditions: Neuropathic pain is frequently a consequence of chronic conditions such as diabetes, shingles, and spinal cord injuries. The escalating prevalence of these conditions, notably diabetes, is a primary driver in the increased demand for effective pain management solutions. In 2019, there were an estimated 20.6 million individuals globally living with spinal cord injuries, with the annual incidence in the United States approximated at 54 cases per one million people. Notably, the prevalence of diabetes among those with spinal cord injuries stands at around 21%, underscoring the significant overlap between these chronic conditions and neuropathic pain.
  2. Growing Awareness and Diagnosis: Enhanced awareness and advancements in diagnostic capabilities are enabling earlier diagnosis and treatment of neuropathic pain. This results in a broader patient demographic actively seeking treatment, thereby stimulating market growth. Studies within the general population have identified that 7–8% of adults experience chronic pain with neuropathic characteristics, with an overall prevalence rate of 14.6% for neuropathic pain.
  3. Demand for Targeted Therapies: Traditional pain management medications often fall short in effectively treating neuropathic pain, leading to an increased demand for targeted therapies. These therapies aim to directly address the root causes of neuropathic pain, such as nerve damage or inflammation, prompting a surge in research and development of novel treatment options.
  4. Focus on Improving Patient Outcomes: The industry is increasingly orienting towards therapies that not only alleviate pain but also enhance the overall well-being and quality of life for patients. This involves treatments that tackle neuropathic pain and its common comorbidities, such as sleep disturbances and depression, ensuring a holistic approach to patient care.
  5. Technological Advancements: Technological innovations are significantly influencing the management of neuropathic pain. This encompasses the development of minimally invasive surgical techniques, neurostimulation therapies, and telehealth platforms for remote patient monitoring and management. The field of neuromodulation, in particular, is experiencing a technological renaissance, promising substantial improvements in chronic pain management. Additionally, digital health tools, including mobile applications and wearable devices, are being utilized to continuously monitor and track pain levels, allowing for dynamic adjustments to treatment regimes.

Market Restraints and Challenges:

Limited Treatment Efficacy and Lack of Novel Therapies:

  • Current treatment options for neuropathic pain often have limited efficacy and can come with significant side effects. Opioids, a common class of medication, can lead to dependence and addiction. Anticonvulsants and antidepressants, while sometimes helpful, can have unpredictable results and tolerability issues. The lack of truly effective and well-tolerated treatment options creates a significant unmet need in the market and frustrates both patients and physicians.

Complex Diagnosis and Heterogeneous Patient Population:

  • Neuropathic pain can arise from various underlying conditions, making diagnosis challenging. This complexity can lead to delays in proper treatment and frustration for patients seeking relief. Additionally, the neuropathic pain population is highly heterogeneous, experiencing pain in different ways and responding differently to medications. Developing targeted therapies for specific types of neuropathic pain would be a significant market advantage.

High Costs of Treatment and Reimbursement Concerns:

  • Neuropathic pain management can be expensive, encompassing medications, physical therapy, and potential surgeries. This can create a barrier to treatment for patients, particularly those with limited healthcare access or high out-of-pocket costs. Additionally, healthcare providers may be hesitant to prescribe certain medications due to concerns over reimbursement by insurance companies. Strategies to reduce treatment costs or demonstrate greater cost-effectiveness compared to traditional options are crucial for wider market adoption.

Stigma and Lack of Awareness:

  • Neuropathic pain can be a debilitating condition, significantly impacting a patient’s quality of life. However, there is still a stigma associated with chronic pain, and many patients may not seek help due to fear of judgment or misunderstanding. Additionally, public awareness of neuropathic pain and its treatment options remains limited. Educational campaigns and initiatives to reduce stigma can encourage more people to seek diagnosis and treatment, ultimately expanding the market.

Slow Pace of Drug Development and Regulatory Hurdles:

  • The development of new and improved treatments for neuropathic pain can be a lengthy and expensive process. Regulatory hurdles can further delay the availability of potentially life-changing therapies for patients. Streamlining the drug development process and fostering greater collaboration between researchers, pharmaceutical companies, and regulatory bodies would be crucial to accelerating the introduction of novel treatments.

Recent Developments:

  • In July 2022, Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited entered into an exclusive collaboration and commercialization agreement for NRD.E1, Novaremed’s innovative non-opioid investigational drug being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.
  • In March 2022, Daiichi Sankyo Company, Limited, got approval to modify the analgesic “Tarlige Tablets” (mirogabalin besilate) indication from “peripheral neuropathic pain” to “neuropathic pain.” Daiichi Sankyo presented a supplementary new drug application (sNDA) for Tarlige Tablets in May 2021 based on the findings of a phase 3 trial in patients with CNP.

Segmentation Analysis:

By Indication:

  • Diabetic neuropathy: This is the leading cause of neuropathic pain, and the segment is expected to hold the largest market share due to the rising prevalence of diabetes globally.
  • Post-Herpetic Neuralgia (PHN): This segment caters to pain following a shingles infection and is expected to experience significant growth due to the aging population, a demographic more susceptible to shingles.
  • Spinal Stenosis: Pain caused by nerve compression in the spine is another sizable segment, driven by the increasing incidence of spinal degenerative conditions.
  • Chemotherapy-Induced Peripheral Neuropathy (CIPN): This segment is driven by the growing use of chemotherapy drugs that can cause nerve damage.
  • Other Indications: This segment includes pain associated with trigeminal neuralgia, HIV/AIDS, and complex regional pain syndrome (CRPS).


By Type

  • Painful diabetic peripheral neuropathy
  • Autonomic Neuropathy
  • Focal Neuropathy
  • Proximal Neuropathy

By Indication

  • Diabetic Neuropathy
  • Spinal Stenosis
  • Chemotherapy-induced peripheral neuropathy

By Diagnosis

  • Imaging
  • Blood tests and physical examination

By Treatment

  • Medications
  • Multimodal Therapy

By End User

  • Hospitals
  • Clinics
  • Research Organization

By Regional

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Key player:

  • Pfizer, Inc.,
  • Johnson & Johnson Services, Inc.,
  • Sanofi S.A.,
  • Eily Lily and Company,
  • GlaxoSmithKline PLC,
  • Biogen Idec.,
  • Bristol-Myers Squibb,
  • Baxter Healthcare Corporation,
  • Depomed, Inc.

Regional Analysis:

  • North America: This region is expected to hold the largest market share due to several factors. These include a high prevalence of conditions causing neuropathic pain like diabetes, a well-established healthcare infrastructure, and a strong focus on research and development of novel treatment options. Additionally, high patient awareness and willingness to adopt new therapies contribute to market growth in North America.
  • Europe: Europe represents a mature market for neuropathic pain treatment, with a robust healthcare system and established reimbursement policies. The aging population in Europe is a significant driver, as the risk of neuropathic pain increases with age. However, stringent regulatory hurdles and cost-containment measures might influence market growth in this region.
  • Asia Pacific: This region is projected to witness the fastest growth in the neuropathic pain market. Factors like rising disposable income, increasing awareness of treatment options, and a growing elderly population are fueling the market expansion. Additionally, the presence of large domestic pharmaceutical companies and ongoing clinical trials are expected to contribute to market growth in the Asia-Pacific region.
  • Latin America and the Middle East and Africa (MEA): These regions are expected to experience moderate growth in the neuropathic pain market. Limited access to advanced healthcare facilities and lower disposable income in some countries might pose challenges. However, growing government initiatives to improve healthcare infrastructure and increasing investments in the pharmaceutical sector in these regions present potential opportunities for market growth.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Future Outlook:

  • Rising Prevalence of Underlying Conditions: The growing burden of diabetes, shingles, and other neuropathic pain-causing conditions will fuel market demand for effective treatment options.
  • Aging Population: As the global population ages, the incidence of age-related neuropathic pain is expected to rise, further propelling market growth.
  • Increasing Healthcare Expenditure: Rising healthcare budgets in developed and developing economies will likely translate into greater investment in neuropathic pain management.
  • Focus on Novel Therapies: Continued research and development efforts will lead to the introduction of novel therapeutic strategies, including targeted drugs and gene therapies, creating exciting possibilities for improved pain management.
  • Growing Awareness and Diagnosis: Increased public awareness and improved diagnostic tools will lead to earlier detection and treatment of neuropathic pain, potentially expanding the patient pool.
  • Expansion of Reimbursement Policies: Broader coverage of neuropathic pain treatments by insurance companies will improve patient access and market growth.
  • Focus on Non-Opioid Pain Management: Growing concerns about opioid dependence will drive the demand for non-opioid pain management solutions, creating opportunities for alternative therapies.
  • Technological Advancements: Technological advancements in drug delivery systems and neuromodulation techniques hold promise for more targeted and effective pain management approaches.
  • Telemedicine and Remote Monitoring: The expanding adoption of telemedicine and remote monitoring technologies can improve patient access to pain specialists and enhance treatment adherence.
  • Focus on Personalized Medicine: The rise of personalized medicine may lead to the development of more individualized treatment plans based on a patient’s specific pain profile and genetics, potentially improving treatment efficacy.

For Table OF Content – Request For Sample Report –

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Frequently Asked Questions:

What factors contribute to the anticipated growth of the neuropathic pain market from USD 8,379.70 million in 2023 to USD 14,535.46 million by 2032, with a CAGR of 5.94%?

The significant growth projections in the neuropathic pain market can be attributed to several key factors. These include the rising prevalence of underlying conditions such as diabetes, an aging global population more susceptible to neurological disorders, and the increased incidence of cancer and associated treatments leading to neuropathic pain. Additionally, improvements in diagnostic tools and increased public awareness are facilitating earlier and more accurate identification of neuropathic pain, contributing to the expanding market.

How are advancements in treatment options addressing the unmet needs in neuropathic pain management?

Despite existing medications and therapies, there is a considerable unmet need for effectively managing neuropathic pain. Ongoing research and development efforts are focused on novel therapeutic approaches that offer improved efficacy and reduced side effects. Furthermore, the market is witnessing a shift towards non-invasive techniques for pain management, presenting opportunities for the development and adoption of innovative treatment options that cater to the diverse needs of neuropathic pain patients.

How do government initiatives and increased healthcare spending influence the neuropathic pain market’s growth?

The neuropathic pain market is benefiting from the global increase in healthcare expenditures, with more resources being allocated to chronic pain management, including neuropathic pain. Governments worldwide are recognizing the burden of chronic pain and implementing supportive initiatives to improve access to pain management therapies. This conducive environment, coupled with increased funding, further propels the development and accessibility of treatment options for a broader patient population.

Can you elaborate on the role of awareness campaigns and educational initiatives in driving the neuropathic pain market expansion?

The growth of the neuropathic pain market is also driven by heightened public awareness and educational initiatives. These campaigns play a crucial role in empowering individuals to seek medical attention for neuropathic pain, leading to a rise in diagnosed cases. With improved diagnostics and early intervention, the market experiences an increased demand for treatment options. The combined impact of awareness and education contributes significantly to the overall expansion of the neuropathic pain market from 2023 to 2032.

Therapeutic Monoclonal Antibodies Market

Report ID: 11175

United States Human Papillomavirus Vaccines Market

Report ID: 36384

White Canes Market

Report ID: 36378

Cancer Profiling Market

Report ID: 36289

Flowable Hemostats Market

Report ID: 36279

Fibrin Sealants Market

Report ID: 36276

Prostate Cancer Market

Report ID: 36273

ECG Telemetry Devices Market

Report ID: 36237

Blotting Systems Market

Report ID: 36233

India Dental Consumables Market

Report ID: 36214

Biotechnology and Pharmaceutical Services Outsourcing Market

Report ID: 36191

India Bariatric Surgery Devices Market

Report ID: 36164

Purchase Options

Delivery Format: Excel.
Designed for the individual purchaser.
Users located at a single corporate site or regional office.
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


+91 6232 49 3207


24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN